| Univ Jena–Thermo Fisher: mass spectrometer, 201806 supply existent |
2018-06-12 |
| RSP Systems–SEVERAL: investment, 201806 financing round Series B first closing €6.5m incl family offices + private investors |
2018-06-11 |
| Roche–Microbiotica: microbiomics, 201806– collab multi-year up to $534m RnD + commerc of markers + targets + treatments for IBD w Genentech |
2018-06-06 |
| Roivant–Oxford BioMedica: Parkinson’s gene therapy, 201806–202203 license ww excl to OXB-102 $30m upfront + $812.5m milestones to Axovant TERMINATED |
2018-06-06 |
| Gilead–Hookipa: therapeutic vaccine technology, 201806– collab + license $10m upfront RnD immunotherapies against HIV + HBV |
2018-06-05 |
| Arvinas–Bayer: investment, 201806 founding agricultural 50/50 joint venture w $55m committed funding from Bayer + techn + IP from Arvinas |
2018-06-04 |
| Bayer–Arvinas: PROTAC technology, 201806– collab agricultural 50/50 joint venture w $55m committed funding from Bayer + techn + IP from Arvinas |
2018-06-04 |
| Secarna–MC Services: public relations, 201806 service existent by MC Services |
2018-06-04 |
| Sierra Sensors–Bruker: investment, 201806 acquisition €na of Sierra Sensors GmbH by Bruker |
2018-06-04 |
| Tricares–Andera Partners: investment, 201806 financing round Series B totalling €22m incl new + co-lead investor Andera Partners |
2018-06-04 |
| Tricares–SEVERAL: investment, 201806 financing round Series B €22m led by Wellington Partners + Andera Partners + BioMedPartners |
2018-06-04 |
| Univ Birmingham–Thermo Fisher: mass spectrometer, 201806 supply existent early customer Orbitrap ID-X Tribrid MS system at PCB |
2018-06-04 |
| Univ Greifswald–Bruker: NMR spectrometer, 201806 supply installation of AVANCE IVDr at Greifswald Univ Hospital) |
2018-06-01 |
| Arix Bioscience–Evotec: drug discovery, 201805–202304 collab partnership LAB591 for early-stage projects out of Fred Hutchinson Cancer Center |
2018-05-31 |
| Arix Bioscience–Fred Hutchinson: drug discovery, 201805–202304 collab partnership LAB591 for early-stage projects out of Fred Hutch with Evotec |
2018-05-31 |
| Evotec–Fred Hutchinson: drug discovery, 201805–202304 collab partnership LAB591 for early-stage projects out of Fred Hutch with Arix Bioscience |
2018-05-31 |
| Qiagen–Freenome: molecular companion diagnostics, 201805– collab co-marketing of CDx solutions for immuno-oncology |
2018-05-31 |
| TxCell–Lonza: cell therapy contract manufacturing, 201805– supply of TX200 for clinical studies by Lonza production site in Geleen (NL) |
2018-05-31 |
| Univ Tübingen–ERS Genomics: CRISPR technology, 201804– license €na to NMI + NMI TT Pharmaservices to expand custom cell-based research services |
2018-05-31 |
| F-Star–Denali Therapeutics: investment, 201805 acquisition of F-Star Gamma Ltd via early exercise of option for asset-centric vehicle |
2018-05-30 |
| Five Prime–Roche: companion diagnostics, 201805– collab €na to develop IHC CDx assays for two cancer antibody candidates |
2018-05-30 |
| Ultra Scientific–Agilent: investment, 201805– acquisition of all business assets €na of Ultra Scientific by Agilent |
2018-05-30 |
| Aldeyra Therapeutics–Centogene: genomic services, 201805– collab identification of genetic markers for Sjögren-Larsson Syndrome using CentoMD |
2018-05-29 |
| Celgene–Evotec: drug discovery services, 201805– strategic RnD collab expansion $6m to incl additional cell lines |
2018-05-29 |
| High-Tech Gründerfonds–Bayer: investment, 201805 Bayer invests in HTGF III |
2018-05-29 |
| High-Tech Gründerfonds–Boehringer: investment, 201805 BIVF invests in HTGF III |
2018-05-29 |
| High-Tech Gründerfonds–SEVERAL: investment, 201805 2nd closing of HTGF III €71.5m bringing total fund size to €316.5m |
2018-05-29 |
| Treeway–Trophic Communications: public relations, 201805 service existent by Trophic |
2018-05-29 |
| Agilent–Univ Duisburg-Essen: analytical technology, 201804– collab with new Agilent sponsored Teaching + Research Center for Separation (TRC) at UDE |
2018-05-24 |
| Lunaphore–Vitro (ES): in situ hybridisation, 201805– collab developm ISH protocols for RNA + DNA targets in tissue |
2018-05-24 |
| Medigene–SEVERAL: investment, 201805 private placement €32.3m 2.23m new shares at €14.5/share to institutional investors |
2018-05-24 |
| Evotec–I’rom Group: iPSC technology, 201805– license non-excl for iPSCs produced with Sendai virus vector technology from ID Pharma |
2018-05-23 |
| Lava Therapeutics–Trophic Communications: public relations, 201805 service existent by Trophic |
2018-05-23 |
| Orphazyme–Centogene: biomarker discovery, 201805– collab service biomarkers for Gaucher disease clinical trial monitoring |
2018-05-23 |
| Samsung–Sphingotec: investment, 201805 acquisition of Nexus Dx Inc from Samsung via joint venture with CEO Nam Shin |
2018-05-22 |
| Celgene–Evotec: drug discovery services, 201805– strategic RnD collab $65m upfront for cancer drugs |
2018-05-21 |
| Pierre Fabre–Roche: companion diagnostics, 201805– collab extension for developm of IHC CDx assay for ADC W0101 |
2018-05-18 |
| Acousia Therapeutics–Boehringer: investment, 201805 financing round Series B totalling €10m incl existing + co-investor BIVF |
2018-05-14 |
| Acousia Therapeutics–Bregua Corp: investment, 201805 financing round Series B totalling €10m incl new + co-investor Bregua Corp |
2018-05-14 |
| Acousia Therapeutics–Creathor Ventures: investment, 201805 financing round Series B totalling €10m incl new + co-investor Creathor Venture |
2018-05-14 |
| Acousia Therapeutics–Germany (govt): investment, 201805 financing round Series B totalling €10m incl existing + co-investor KfW |
2018-05-14 |
| Acousia Therapeutics–Instinctif Partners: public relations, 201805 service existent by Instinctif |
2018-05-14 |
| Acousia Therapeutics–LBBW: investment, 201805 financing round Series B totalling €10m incl lead + new investor LBBW Venture Capital |
2018-05-14 |
| Acousia Therapeutics–SEVERAL: investment, 201805 financing round Series B €10m led by new investor LBBW Venture Capital |
2018-05-14 |
| Bluebird Bio–Medigene: TCR technology, 201805– collab strategic alliance expansion incl $8m one-time payment |
2018-05-14 |
| Polyneuron–SEVERAL: investment, 201805 seed financing round CHF3.1m led by EVA Basel + incl Zürcher Kantonalbank + private investors |
2018-05-14 |
| Valerius Biopharma–Catalent: contract manufacturing, 201805– collab cell line developm + manufacturing of speciality biosimilars using GPEx technology |
2018-05-14 |
| Armo BioSciences–Lilly: investment, 201805– acquisition $1.6b cash tender offer at $50/share by Eli Lilly |
2018-05-10 |
| Memo Therapeutics–Redalpine: investment, 201805 financing round Series A2 totalling CHF5m incl existing investor Redalpine Venture Partners |
2018-05-09 |
| Memo Therapeutics–Schroders: investment, 201805 financing round Series A2 totalling CHF5m incl new investor Schroder Adveq |
2018-05-09 |
| Memo Therapeutics–SEVERAL: investment, 201805 financing round Series A2 CHF5m incl Schroder Adveq + investiere.ch + Redalpine Ventures et al. |
2018-05-09 |
| Memo Therapeutics–Verve Capital Partners: investment, 201805 financing round Series A2 totalling CHF5m incl new investor investiere.ch |
2018-05-09 |
| Memo Therapeutics–Zürcher Kantonalbank: investment, 201805 financing round Series A2 totalling CHF5m incl existing investor ZKB |
2018-05-09 |
| PHAST–Eurofins: investment, 201805 acquisition of PHAST GmbH by Eurofins Scientific |
2018-05-09 |
| Bruker–CMS: legal services, 201805 service legal advice by CMS on acquisition of Sierra Sensors GmbH by Bruker |
2018-05-06 |
| Bruker–CMS: legal services, 201808 service legal advice by CMS on majority acquisition of Hain Lifescience by Bruker |
2018-05-06 |
| InflaRx–LifeSci: public relations, 201805 service existent IR by LifeSci Advisors + Media US by LifeSci Public Relations |
2018-05-03 |
| SmartDyeLivery–SEVERAL: investment, 201805 financing round from new investor STIFT + existing investors bm|t + Sparkasse Jena-Saale-Holzland |
2018-05-03 |
| Unisensor (BE)–Scienion: print/spotting technology, 201805 collab use of sciFlexarrayer techn for Extenso milk analysis platform |
2018-05-03 |
| Evotec–ERS Genomics: CRISPR technology, 201804– license €na to expand Evotec’s CRISPR-based service offering from ERS Genomics Ltd |
2018-05-02 |
| Genohm–Agilent: investment, 201805 acquisition €na of Genohm by Agilent |
2018-05-02 |
| InflaRx–SEVERAL: investment, 201805 primary public offering $51m+$7.65m w 1.5m+225k common shares at $34/share |
2018-05-02 |
| AdvanceCor–SEVERAL: investment, 201805 financing round €6m led by MIG AG + incl Occident Group + Bayern Kapital + HTGF + KfW Bank + founders |
2018-05-01 |
| Crescendo Biologics–SEVERAL: investment, 201805 financing round Series B €57m led by Andera Partners |
2018-04-30 |
| NovellusDx–SEVERAL: investment, 201804 financing round $6m incl investors Helsinn + BCIF + Windham Venture Partners |
2018-04-30 |
| Roche–4D Molecular Therapeutics: gene delivery technology, 201804– collab expansion to develop + commercialise ophthalmic gene therapy products |
2018-04-30 |
| Roivant–SEVERAL: investment, 201804 financing round $40.5m of Datavant led by Roivant Sciences + Travis May |
2018-04-30 |
| Universal Patient Key–Roivant: investment, 201804 acquisition of UPK by Datavant |
2018-04-30 |
| Curetis–Global Corporate Finance: investment, 201804–202103 equity facility $10m solely at Curetis request up to 36 months at pre-agreed floor pricing |
2018-04-27 |
| Curetis–SEVERAL: investment, 201804 capital increase €4.1m offering of 854k new ordinary shares at €4.8/share to qualified EU + US investors |
2018-04-27 |
| Polyphor–Consilium: public relations, 201804 service existent international media relations by CSC |
2018-04-27 |
| Corvidia Therapeutics–SEVERAL: investment, 201804 financing round Series B $60m led by Venrock |
2018-04-25 |
| Boehringer–Topas Therapeutics: immuno modulatory compounds, 201804– collab €na multi-y research + option agreem |
2018-04-24 |
| Freenome–Biognosys: proteomic technology, 201804– collab enhancing circulating NA cancer test with proteomics data |
2018-04-24 |
| Revolution Medicines–Nextech: investment, 201804 financing round Series B totalling $56m incl lead investor Nextech Invest |
2018-04-24 |
| Revolution Medicines–SEVERAL: investment, 201804 financing round Series B $56m led by Nextech Invest |
2018-04-24 |
| Bosch–Randox: point-of-care diagnostics, –201804 collab developm test panels for Vivalytic POC analyser |
2018-04-21 |
| Merck (DE)–P&G: investment, 201804 acquisition €3.4b in cash of Merck’s consumer healthcare by P&G |
2018-04-19 |
| AiCuris–Max Planck: anti-infectives, 2018004– collab discovery of antibiotics + virostatic compounds extending existent collab with MPI-MP |
2018-04-18 |
| InterAx Biotech–LeadXPro: cancer immunotherapy, 201804– collab €na drug discovery + optimisation of lead molecules targeting GPCRs |
2018-04-18 |
| Novartis–Pear Therapeutics: digital health, 201804– collab developm + commercialisation of prescripition digital therapeutics for drug abuse Sandoz |
2018-04-18 |
| Tizona Therapeutics–Minapharm: biopharma production, 201804– supply service cell line + process developm + production of therap antibody by ProBioGen |
2018-04-18 |
| Anasys Instruments–Bruker: investment, 201804 acquisition of Anasys by Bruker |
2018-04-17 |
| DiaMan–GlucoMe: digital health, 201804– collab product integration of GlucoMe + DiaMan products + marketing in Central America by DiaMan |
2018-04-17 |
| DKSH–Bruker: analytical instruments, 201804– distribution multi-product line of Bruker AXS in KR + AU + NZ + SG + ID by DKSH Technology |
2018-04-17 |
| Biovertis–Deinove: investment, 201804–201805 acquisition of Biovertis/Morphochem for €900k in 500k new shares + 8m warrants |
2018-04-13 |
| Enterprise Therapeutics–Novartis: investment, 201804 financing round Series B totalling £29m ($41m) incl co-lead investor Novartis Venture Fund |
2018-04-12 |
| Enterprise Therapeutics–SEVERAL: investment, 201804 financing round Series B £29m ($41m) co-led by Versant Ventures + NVF |
2018-04-12 |
| Knauer–Microsaic: mass spectrometry, 201804– collab integration of Microsaic’s compact MS techn in Knauer’s LC platform |
2018-04-12 |
| Shire–Takeda: investment, 201804–201901 acquisition $62.2b (incl debt approx $80b) for $30.33 per share in cash + 0.839 Takeda shares per share |
2018-04-12 |
| Petra Pharma–Evotec: drug development services, 201804– supply service €na support developm of Petra-01 through to IND |
2018-04-11 |
| Roivant–Arbutus Biopharma: RNA drugs, 201804– collab founding of jv Genevant Sciences to develop RNA drugs using LNP technology |
2018-04-11 |
| Baliopharm–Promethera: investment, 201804 acquisition €na of Baliopharm AG by Promethera Biosciences SA |
2018-04-10 |
| Boehringer–Biomax: bioinformatics, 201804– license multi-year for BioXM s/w + license extension for BioRS s/w |
2018-04-10 |
| Promethera–MacDougall Biomedical Communications: public relations, 201804 service existent by MacDougall |
2018-04-10 |
| AveXis–Novartis: investment, 201804–201805 acquisition $8.7b in cash of AveXis Inc by Novartis for $128/share |
2018-04-09 |
| Grünenthal–Univ Leuven: pain drugs, 201804– collab RnD non-opioid pain drugs with CD3 + LICR |
2018-04-09 |
| Polyphor–SEVERAL: investment, 201804–201805 IPO CHF155m (€130m) at SIX Swiss Exchange at CHF38/share |
2018-04-09 |
| Rebiotix–Ferring: investment, 201804 acquisition of Rebiotix by Ferring |
2018-04-05 |
| Arvinas–Nextech: investment, 201804 financing round Series C totalling $55m incl new + lead investor Nextech Invest |
2018-04-04 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 ... 33 34 35 ... 42 43 44 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
